{
    "name": "incobotulinumtoxinA",
    "comment": "Rx",
    "other_names": [
        "Xeomin"
    ],
    "classes": [
        "Neuromuscular Blockers",
        "Botulinum Toxins"
    ],
    "source": "https://reference.medscape.com/drug/xeomin-incobotulinumtoxina-999589",
    "pregnancy": {
        "common": [
            "There are no adequate data on the developmental risk associated with the use of incobotulinumtoxinA in pregnant women",
            "Use during pregnancy only if the potential benefit justifies the potential risk to the fetus"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "IncobotulinumtoxinA was embryotoxic in rats and increased abortions in rabbits when given at doses higher than the maximum recommended human dose (MRHD) for cervical dystonia (120 units), on a body weight basis"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence in human milk, the effects on the breastfed infant, or the effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Distant spread of toxin effect",
                    "description": [
                        "Botulinum toxin products may spread from injected area to produce symptoms consistent with botulinum toxin effects (eg, asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, respiratory distress)",
                        "These symptoms have been reported hours to weeks after injection"
                    ]
                },
                {
                    "type": "Swallowing and breathing difficulties",
                    "description": [
                        "Can be life threatening and there have been reports of death",
                        "Greatest risk in children treated for spasticity",
                        "Can also occur in adults, particularly in those with underlying conditions that would predispose them to these symptoms (eg, peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders [myasthenia gravis, Lambert-Eaton syndrome])"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Infection at proposed injection site(s)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Dose NOT interchangeable with other botulinum toxin products",
                "Symptoms consistent with spread of toxin effect reported at doses comparable to or lower than doses used to treat cervical dystonia",
                "Can cause swallowing and breathing difficulties, caution with compromised respiratory function or dysphagia",
                "Concomitant neuromuscular disorders may exacerbate adverse effects",
                "Serious hypersensitivity reactions reported with botulinum toxin products, including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea; if serious and/or immediate hypersensitivity reactions occur, discontinue further injections and institute appropriate medical therapy immediately",
                "Discontinue and immediately initiate medical therapy if hypersensitivity reaction occurs (eg, anaphylaxis, serum sickness, urticaria, edema, dyspnea)",
                "This product contains albumin, a derivative of human blood; based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases; consider a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD)"
            ],
            "specific": [
                {
                    "type": "Cervical dystonia",
                    "description": [
                        "Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia",
                        "Limit dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia"
                    ]
                },
                {
                    "type": "Blepharospasm",
                    "description": [
                        "Injection into orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation",
                        "Lower lid injections should not be repeated if diplopia occurred with previous botulinum toxin injections",
                        "Ecchymosis easily occurs in the soft tissues of the eyelid",
                        "Immediate gentle pressure at the injection site can limit that risk"
                    ]
                },
                {
                    "type": "Glabellar lines",
                    "description": [
                        "Risk of ptosis",
                        "Do not exceed the recommended dosage and frequency of administration",
                        "To reduce the complication of ptosis, avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes, and place corrugator injections at least 1 cm above the bony supraorbital ridge"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Coadministration with aminoglycosides or other agents interfering with neuromuscular transmission (eg, tubocurarine-type muscle relaxants) may potentiate the effect of the toxin; use with caution",
                        "Use of anticholinergic drugs after administration of incobotulinumtoxinA may potentiate systemic anticholinergic effects; effects of administering different botulinum toxin products at the same time or within several months of each other is unknown",
                        "Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin",
                        "Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of incobotulinumtoxinA"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abobotulinumtoxinA",
            "description": {
                "common": "incobotulinumtoxinA, abobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Effect of administering different botulinum toxins simultaneously or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to resolution of the effects of a previously administered botulinum toxin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amphotericin B deoxycholate",
            "description": {
                "common": "amphotericin B deoxycholate increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gentamicin",
            "description": {
                "common": "gentamicin increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glycopyrronium tosylate topical",
            "description": {
                "common": "glycopyrronium tosylate topical, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "neomycin PO",
            "description": {
                "common": "neomycin PO increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "onabotulinumtoxinA",
            "description": {
                "common": "onabotulinumtoxinA, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Effect of administering different botulinum toxins simultaneously or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to resolution of the effects of a previously administered botulinum toxin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "polymyxin B",
            "description": {
                "common": "polymyxin B increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of resp. depression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prabotulinumtoxinA",
            "description": {
                "common": "prabotulinumtoxinA, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Effect of administering different botulinum toxins simultaneously or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to resolution of the effects of a previously administered botulinum toxin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pramlintide",
            "description": {
                "common": "pramlintide, incobotulinumtoxinA. pharmacodynamic synergism. Avoid or Use Alternate Drug. Synergistic inhibition of GI motility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "streptomycin",
            "description": {
                "common": "streptomycin increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tobramycin",
            "description": {
                "common": "tobramycin increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of apnea."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anticholinergic/sedative combos",
            "description": {
                "common": "anticholinergic/sedative combos, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arbaclofen",
            "description": {
                "common": "arbaclofen, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atracurium",
            "description": {
                "common": "atracurium increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Neuromuscular blockers may enhance the effects of prabotulinumtoxinA. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atropine",
            "description": {
                "common": "atropine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "baclofen",
            "description": {
                "common": "baclofen, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna alkaloids",
            "description": {
                "common": "belladonna alkaloids, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benperidol",
            "description": {
                "common": "benperidol, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benztropine",
            "description": {
                "common": "benztropine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "capreomycin",
            "description": {
                "common": "capreomycin increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carisoprodol",
            "description": {
                "common": "carisoprodol, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpromazine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorzoxazone",
            "description": {
                "common": "chlorzoxazone, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clindamycin",
            "description": {
                "common": "clindamycin increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Aminoglycosides may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "cyclobenzaprine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dantrolene",
            "description": {
                "common": "dantrolene, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "diazepam, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dimenhydrinate",
            "description": {
                "common": "dimenhydrinate, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "droperidol increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "fluphenazine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "huperzine A",
            "description": {
                "common": "huperzine A increases and incobotulinumtoxinA decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "loxapine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "loxapine inhaled, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaxalone",
            "description": {
                "common": "metaxalone, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methocarbamol",
            "description": {
                "common": "methocarbamol, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "orphenadrine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Muscle relaxants may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "pimozide increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "prochlorperazine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "promethazine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "quetiapine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "risperidone, incobotulinumtoxinA.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases effects of incobotulinumtoxinA by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases effects of incobotulinumtoxinA by Other (see comment). Use Caution/Monitor. \nComment: Magnesium may potentiate the effects of the neuromuscular blocking agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "thioridazine increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiotepa",
            "description": {
                "common": "thiotepa increases levels of incobotulinumtoxinA by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "thiothixene increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin inhaled",
            "description": {
                "common": "tobramycin inhaled increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Aminoglycosides may aggravate muscle weakness because of a curare-like effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "trifluoperazine increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide decreases effects of incobotulinumtoxinA by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amlodipine",
            "description": {
                "common": "amlodipine increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "nisoldipine increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases effects of incobotulinumtoxinA by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rufinamide",
            "description": {
                "common": "rufinamide decreases effects of incobotulinumtoxinA by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane increases levels of incobotulinumtoxinA by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tiagabine",
            "description": {
                "common": "tiagabine decreases effects of incobotulinumtoxinA by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate decreases effects of incobotulinumtoxinA by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": "23-32"
        },
        {
            "name": "Dysphagia",
            "percent": "13-18"
        },
        {
            "name": "Nervous system disorders",
            "percent": "16-17"
        },
        {
            "name": "General disorders and administration site condition",
            "percent": "11-16"
        },
        {
            "name": "Neck pain",
            "percent": "7-15"
        },
        {
            "name": "Infections and infestations",
            "percent": "13-14"
        },
        {
            "name": "Respiratory",
            "percent": "10-13"
        },
        {
            "name": "thoracic",
            "percent": "7-11"
        },
        {
            "name": "and mediastinal disorders",
            "percent": "19"
        },
        {
            "name": "Muscular weakness",
            "percent": "16"
        },
        {
            "name": "Eyelid ptosis",
            "percent": "16"
        },
        {
            "name": "Dry eye",
            "percent": "14"
        },
        {
            "name": "Xerostomia",
            "percent": "12"
        },
        {
            "name": "Nervous system disorders",
            "percent": "11"
        },
        {
            "name": "Visual impairment",
            "percent": "5"
        },
        {
            "name": "including blurred vision",
            "percent": "4"
        },
        {
            "name": "Respiratory",
            "percent": "4"
        },
        {
            "name": "thoracic",
            "percent": "4"
        },
        {
            "name": "and mediastinal disorders",
            "percent": "3"
        },
        {
            "name": "Tooth extraction",
            "percent": "3"
        },
        {
            "name": "Dry mouth",
            "percent": "3"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "Hypertension",
            "percent": "3"
        },
        {
            "name": "Fall",
            "percent": "3"
        },
        {
            "name": "Bronchitis",
            "percent": "2"
        },
        {
            "name": "Dysphonia",
            "percent": "2"
        },
        {
            "name": "Back pain",
            "percent": "2"
        },
        {
            "name": "Dry eye",
            "percent": "9"
        },
        {
            "name": "Seizure",
            "percent": "7"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "7"
        },
        {
            "name": "Dry mouth",
            "percent": "4-7"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "8"
        },
        {
            "name": "Injection site pain",
            "percent": "7"
        },
        {
            "name": "Neck pain",
            "percent": "5"
        },
        {
            "name": "Muscular weakness",
            "percent": "5"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "5"
        },
        {
            "name": "Diarrhea",
            "percent": "5.4"
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Nasopharyngitis",
            "percent": null
        },
        {
            "name": "Respiratory tract infection",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Injection site hematoma",
            "percent": null
        },
        {
            "name": "Injection site pain",
            "percent": null
        },
        {
            "name": "Facial pain",
            "percent": null
        },
        {
            "name": "Injection site swelling",
            "percent": null
        },
        {
            "name": "Sensation of pressure",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Eyelid edema",
            "percent": null
        },
        {
            "name": "Blepharospasm",
            "percent": null
        },
        {
            "name": "Eyelid ptosis",
            "percent": null
        }
    ]
}